Log In
BCIQ
Print this Print this
 

PD-0325901/PF-05212384

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionCombination of PD-0325901 (MEK inhibitor) plus PF-05212384 (PI3K/mTOR inhibitor)
Molecular Target MEK ; Phosphoinositide 3-kinase (PI3K)
Mechanism of ActionMammalian target of rapamycin (mTOR) kinase inhibitor; MEK inhibitor; Phosphoinositide 3-kinase (PI3K) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat advanced cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today